These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830 [Abstract] [Full Text] [Related]
5. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Heller S, Koenen C, Bode B. Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879 [Abstract] [Full Text] [Related]
7. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Kabadi UM. Clin Drug Investig; 2008 Oct; 28(11):697-701. PubMed ID: 18840012 [Abstract] [Full Text] [Related]
12. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331 [Abstract] [Full Text] [Related]
14. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170 [Abstract] [Full Text] [Related]
15. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154 [Abstract] [Full Text] [Related]
16. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F. Diabetes Care; 2010 Jun; 33(6):1176-8. PubMed ID: 20200301 [Abstract] [Full Text] [Related]
17. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Fadini GP, de Kreutzenberg SV, Mariano V, Boscaro E, Bertolini F, Mancuso P, Quarna J, Marescotti M, Agostini C, Tiengo A, Avogaro A. Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861 [Abstract] [Full Text] [Related]